11/25/2025
Why are your premiums high?
Want to understand how the U.S. medical device industry really works?
Don’t follow the technology.
Follow the reimbursements.
This isn’t a free market.
It’s a tightly controlled growth machine built on the Centers for Medicare and Medicaid (CMS) payment policy and protected by the American Hospital Association.
Device companies scale by riding procedure volume and procedure volume is manufactured by how CMS pays.
Raise payment for joints?
Implant sales spike.
Green light electrophysiology?
EP labs explode.
Offer add-ons for robotics? Hospitals rush to buy da Vinci machines they can barely operate.
Health Systems, with the American Hospital As****es (AHA) as their PR and legal shield, use site-of-service markups and facility fees to justify outrageous pricing.
That margin?
It buys the devices.
It funds the expansion.
It locks in procurement deals.
It feeds consolidation.
This is excellence in strategy.
Large systems mean predictable volumes and long-term tech loyalty.
The device sector loves it.
That’s why med device lobbyists sing in harmony with CMS and the AHA, not out of shared values, but shared incentives.
So what threatens this cozy triad?
Independent docs.
Site-neutral payments.
Price transparency.
In other words: competition.
That’s the battle line.
Don’t mistake opposition to reform as a policy debate.
It’s just margin defense.